Neihulizumab

Names

[ Name ]:
Neihulizumab

Biological Activity

[Description]:

Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research[1].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Inflammation/Immunology

[In Vitro]

Neihulizumab 是一种针对 P-选择素糖蛋白配体-1 (PSGL-1) 的单克隆抗体。Neihulizumab 与人 PSGL-1 结合，从而优先诱导晚期活化 T 细胞的凋亡。在炎症部位，血管内皮表达 P-选择素，活化的 T 细胞与这些部位结合并通过 PSGL-1 的表达迁移。以这种方式，Neihulizumab 被认为靶向活化的 T 细胞并抑制运输到发炎组织部位[1]。

[References]

[1]. Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557.

[2]. Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood (2022) 140 (Supplement 1): 10495-10497.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.